Geographic Atrophy Clinical Trials 2024

What are the top hospitals conducting geographic atrophy research?

When it comes to cutting-edge clinical trials in the field of geographic atrophy, several hospitals have emerged as leaders. In Hagerstown, Maryland, Cumberland Valley Retina Consultants is making significant strides with four active trials focused on this condition. With a history of six completed geographic atrophy trials and their first recorded trial dating back to 2019, this hospital's dedication to advancing knowledge and treatment options for patients is commendable. Similarly, East Florida Eye Institute in Stuart has also embraced the challenge with four ongoing clinical trials specifically targeting geographic atrophy. Since their inaugural trial in 2018, they have conducted a total of six studies dedicated to understanding and combating this degenerative eye disease.

In Bellaire, Texas, Retina Consultants of Texas stands out as another leading institution committed to uncovering breakthroughs in the understanding and treatment of geographic atrophy. With four active clinical trials currently underway and a noteworthy seven completed studies since their first recorded trial in 2019, their contributions are invaluable to both patients and researchers alike. Meanwhile, on the West Coast in Poway near San Diego lies Retina Consultants San Diego - an establishment renowned for its dedication towards tackling geographic atrophy through three ongoing clinical investigations along with eight previously conducted ones since launching its first study back in 2018.

Finally yet importantly based out Walnut Creek California Bay Area Retina Associates plays its part by actively conducting three current Geographic Atropy research programs while being affiliated with eight comparative previous scientific efforts from advantageous location holding many years worth medical wisdom; starting off way back around year 2014.

These esteemed institutions demonstrate that when it comes to researching geographic atrophy – a progressive degeneration of retinal tissue leading to vision loss – innovative minds across various locations are working diligently toward finding solutions. Through these collaborative efforts between healthcare professionals and dedicated participants who enroll in these groundbreaking studies we can aspire towards mitigating suffering caused by such eyesight threatening conditions ultimately paving ways towards brighter and clearer future for those affected by geographic atrophy.

Which are the best cities for geographic atrophy clinical trials?

Hagerstown, Maryland; Dallas, Texas; Phoenix, Arizona; Cleveland, Ohio; and San Antonio, Texas are among the best cities for geographic atrophy clinical trials. These cities offer individuals access to a variety of active trials focused on finding effective treatments for this condition. With 10 active trials each in Hagerstown and Dallas studying ANX007, PEGCETACOPLAN (APL-2), LBS-008, Tinlarebant, Avacincaptad pegol 2 mg intravitreal injection and more. Meanwhile Phoenix and Cleveland have 9 active trials exploring IONIS-FB-LRx and Danicopan alongside others. San Antonio also contributes to research with 8 active studies investigating Arm B: JNJ-81201887 High dose along with ANX007 and PEGCETACOPLAN (APL-2). These cities serve as hubs for innovative research that brings hope to those affected by geographic atrophy.

Which are the top treatments for geographic atrophy being explored in clinical trials?

Exciting developments are taking place in the realm of geographic atrophy, with clinical trials exploring potential treatments. OpRegen takes center stage with one active trial and being the first listed treatment for geographic atrophy in 2023. Another promising contender is Avacincaptad pegol, offering hope through its intravitreal injection method. With one active trial and a first listing in 2022, it shows great potential to address this condition. These ongoing trials bring optimism for patients battling geographic atrophy as researchers work towards breakthrough solutions.

What are the most recent clinical trials for geographic atrophy?

Exciting advancements are being made in the field of geographic atrophy, with several recent clinical trials offering hope for patients. Among these trials is a Phase 1/2 study evaluating the efficacy and safety of low-dose administration for geographic atrophy treatment. Another promising trial involves LBS-008, Tinlarebant, which has entered Phase 3 testing to assess its potential benefits in combating this condition. Additionally, CT1812 is undergoing a Phase 2 trial involving the use of a 200 mg dose specifically targeted towards geographic atrophy patients. Other ongoing studies include Part 1 and OpRegen, both in Phase 2 stages and showing promise as potential treatments for this debilitating disease. These latest clinical trials hold tremendous potential for improving outcomes and quality of life for those affected by geographic atrophy.

What geographic atrophy clinical trials were recently completed?

Several significant clinical trials investigating treatments for geographic atrophy have recently been completed, showcasing advancements in this field. In December 2020, a trial sponsored by Hoffmann-La Roche successfully concluded their study on RO7303359. Another noteworthy trial sponsored by NGM Biopharmaceuticals, Inc., testing the effectiveness of NGM621 reached completion in July 2020. Meanwhile, Stealth BioTherapeutics Inc.'s investigation into Subcutaneous elamipretide through the elamipretide delivery system was finalized in March 2019. Notably, Apellis Pharmaceuticals, Inc. conducted two separate trials on APL-2 that were both finished in August 2018 and University of California San Francisco explored Metformin's potential as a treatment for geographic atrophy before concluding their research in April 2016. These extensive efforts highlight the growing dedication to finding effective therapies for individuals affected by this condition.